Gustafson Mark's Form 4 filing
Alzamend Neuro, Inc. (ALZN) · filed Dec 16, 2021
- Accession no.
- 0001214659-21-013288
- Filed
- Dec 16, 2021
- Trade date
- Dec 14, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $57.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gustafson MarkCIK 0001303996 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2021 | Common Stock | SSaleDisposed | −20,000 | $2.85F1 | −$57,000 | 30,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.8543. The range of sale prices on the transaction date was $2.85 to $2.87 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price
Referenced by the price of 1 transaction in Table I.